Results: Twenty-four participants completed the trial (taping, n = 13; control, n = 11). Groups were comparable in age, although the control group contained more men (n = 3 versus n = 0) and scored slightly lower on most outcome measures at baseline. Descriptive analysis favoured the taping group for most outcome measures.
further vertebral fracture (Huang, Barrett-Connor, Greendale, & Kado, 2006) . OVFs cause significant pain and impact on function and quality of life (QoL) (Sanfélix-Genovés, Hurtado, Sanfélix-Gimeno, Reig-Molla, & Peiró, 2011; Yoon et al., 2014) . A recent systematic review and meta-analysis showed reduced QoL with OVF, with greater effects on physical than mental components (Al-Sari, Tobias, & Clark, 2016) .
Pain following vertebral fracture is one of the most important determinants of QoL (Nevitt et al., 1998) . Vertebral fracture has an impact on sleep, emotional health and mobility (Francis et al., 2004) , and thus presents a major challenge to patients and healthcare services.
In addition to medication for pain relief and underlying osteoporosis, nonpharmacological interventions such as physiotherapy to improve pain and mobility, and to reduce the number of falls and future fractures are advocated (Francis et al., 2004; Sinaki, 2012) . A Cochrane review exploring the effects of exercise for OVF (Giangregorio, MacIntyre, Thabane, Skidmore, & Papaioannou, 2013) identified some limited support for effects on pain, physical function and QoL but the small number of low-quality trials was highlighted. Other systematic reviews have explored the effects of spinal orthoses and taping (Goodwin, Hall, Rogers, & Bethel, 2016; Newman, Minns Lowe, & Barker, 2016) , identifying a lack of evidence for effectiveness and the low quality of existing research. All reviews recommended further high-quality studies.
Taping to correct posture is a potentially useful addition to rehabilitation following OVF. Posture correction may reduce spinal loading, pain and, in the longer term, risk of further fractures. Postural taping might also improve proprioceptive input, reduce pain and assist engagement in functional activity. Taping has been shown to be effective when used as part of a complex rehabilitation package including other techniques such as manual therapy and exercise, reducing thoracic kyphosis (Bautmans, van Arken, van Mackelenberg, & Mets, 2010) and improving pain and function (Bennell et al., 2010) . Postural taping is also part of a "manual therapy" intervention in an ongoing large trial (n = 600) of rehabilitation for patients with OVF (Barker et al., 2014) . The only study of postural taping used in isolation for osteoporosis was a small (n = 15) crossover study by Greig, Bennell, Briggs, and Hodges (2008) , which found that taping reduced thoracic kyphosis, although it did not alter balance or muscle activity. In that study, the effects of tape were assessed during a single session, so longer-term effects are unknown. Pain or other clinical outcomes were not included, and a potential drawback with the taping technique used (Greig et al., 2008) is the need for trained therapists to apply it on an ongoing basis. Arguably, therefore, it represents an unlikely long-term treatment solution. Novel postural taping devices-for example, Posture Pals ® (http://www.posturepals.com.au) and PosturePlast (http://www.postureplast.co.uk)-negate the need for skilled application and could be a more accessible and cost-effective alternative.
Of course, such devices could also prove to be ineffective, a finding that could equally help to inform practice. The intervention used in the present investigation, PosturePlast, has previously only been evaluated in a small unpublished cohort study (n = 92) of patients with low back pain (Postureplast, 2018) . After 1 week, 83% reported that it was useful for improving posture, 90% that it prevented poor posture and 78% that it improved pain. Rigorous independent evaluations have yet to be conducted.
The aim of the present feasibility randomized, controlled trial (RCT) was therefore to undertake a preliminary investigation of the effects of a novel postural taping device on pain, function and QoL following OVF when used for a 4-week period in addition to usual care. A primary intention was to inform the development of a future definitive RCT.
| METHODS
The study was approved by the West Midlands South Birmingham National Research Ethics Service Committee (13/WM/0357).
| Recruitment
Men and women diagnosed with OVF from two secondary care organizations in South West England were invited to participate in the study.
Inclusion criteria included:
1. Back pain concurrent with a diagnosis of OVF. OVF was confirmed by a rheumatologist trained in the algorithm-based qualitative (ABQ) method of identifying OVF from spinal radiographs (Ferrar, Jiang, Schousboe, DeBold, & Eastell, 2008) . The ABQ method is the most specific and reproducible method of OVF identification for research purposes, with a low false-positive rate.
2. Fracture not immobilized.
3. Independently mobile (with or without an aid).
4. Able to apply the postural taping device to the low back independently or with assistance.
Exclusion criteria included:
1. Osteoporosis secondary to metabolic bone disorders or other disease (steroid-induced osteoporosis was not an exclusion criterion).
2. Fragile or broken skin.
3. Known allergy to adhesive plasters.
Vertebroplasty or kyphoplasty.
Potential participants were identified prospectively by physiotherapy, osteoporosis and spinal services and sent study information.
Interested participants returned a reply slip to the research team, who then telephoned to check eligibility and answer any questions.
If potential participants gave verbal consent, a mutually convenient appointment was agreed for baseline assessment. On attendance, further opportunity was given for questions before formal written informed consent and completion of study outcomes.
| Outcome measures
Outcomes were assessed at baseline and at 4 weeks. The exploratory nature of the trial and limited resources meant that longer-term follow-up was not possible. Pain at rest and on movement was assessed using two 10 cm visual analogue scales (VASs), with anchors of "No pain" and "Pain as bad as it could be". Participants were asked to:
"Place a vertical mark on each line below to indicate how bad you feel your back pain is today…" "… at rest" and "… on movement". Function and QoL were assessed using the 41-item Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41) (Lips et al., 1999) . The QUALEFFO contains 41 questions with Likert scale responses which produce a total score and separate subscales for pain, physical function, social function, general health perception and mental function. The total score and each subscale give a maximum score of 100, with higher scores representing increased severity.
The QUALEFFO-41 has been well validated (de Oliveira Ferreira et al., 2009; Lips et al., 1999; Tadic et al., 2012) . Demographics (at baseline), healthcare resource use (at baseline and week 4) and acceptability of the taping device and outcome measures (at week 4) were assessed using specifically designed questionnaires. The wording of questions is reported in the results section.
| Interventions
Following baseline assessment, participants were randomly allocated to receive the taping device for home use or to continue with usual care. Those receiving taping received full instruction and a supply of
devices. An instruction booklet, including information on skin care
and research team contact details, was issued. The taping device is a large adhesive plaster with a built-in flexible plastic "X" (see Figure 1 ). According to the manufacturer, it is designed to control back movement, reduce pain and improve posture (http://www.postureplast.co. uk). The device is designed for the lumbar spine and was applied in accordance with the manufacturer's guidelines but with the aim of influencing posture throughout the spinal column. This rationale was supported by previous evidence that a soft lumbar orthosis reduced thoracic kyphosis in a sub-sample of patients with OVF (Li, Law, Cheng, Kee, & Wong, 2015) . Participants were advised to wear the device as often as they felt they needed or wanted to. Although each device could only be used once, participants could wear each for up to 48 hr, and could sleep and shower with it on. Participants were supplied, free of charge, with sufficient devices so that they could use a new one every day if they wished. When purchased as a pack of 10, the devices normally cost approximately £2.50 each (cost correct at the time of submitting the manuscript).
Participants randomized to the control condition simply continued with "usual care". The resource use questionnaire collected information about what that constituted. The research team did not provide any additional advice or intervention. All participants were given a follow-up appointment four weeks later.
| Randomization
An independent monitor prepared sealed opaque envelopes containing random treatment allocations. The sequence was generated using an online randomization tool (http://www.random.org). Block randomization (1:1 allocation) was used (block size was four but the research associate was blinded to block size). Randomization was not stratified.
Envelopes were numbered sequentially. Following consent, participants were allocated a sequential study number and, following baseline assessment, the corresponding envelope was opened to reveal their treatment allocation.
| Blinding
Due to the nature of the interventions, it was not possible to blind patients or the research associate to treatment allocations. However, data analysis was conducted blind to treatment allocations. Clinical outcomes were patient self-reported, so the potential impact of lack of researcher blinding was moderated, although it could not be discounted. The experimental procedure is summarized in Figure 2 .
| Sample size
As this was a feasibility study, a sample size calculation was not performed. Recommendations for such studies vary. Julious (2005) recommended at least 12 per group for a parallel group trial and Hertzog (2008) recommended 10-20 per group for estimating variance to inform power analysis. The maximum sample size was set at 20 per group, although 10-12 per group was anticipated to be sufficient for effect size estimates.
| Data analysis
As this was a feasibility study, inferential analysis was inappropriate.
Descriptive statistics (mean, standard deviation, standardized effect size and 95% confidence intervals [CIs]) estimated outcome variability and between-group differences, and informed sample size calculations for a future RCT.
3 | RESULTS
| Recruitment
A Consolidated Standards of Reporting Trials (CONSORT) flow diagram is presented in Figure 3 . A total of 74 potentially eligible patients were sent recruitment packs, and 25 of these (34%) consented and were randomized to the control (n = 12) and taping (n = 13) arms.
One control group participant failed to attend follow-up (4% attrition) and was excluded. Twenty-four patients were therefore included in the data analysis (n = 11 control and n = 13 taping). FIGURE 1 Postural taping device in situ Participant characteristics and baseline outcomes are presented in Table 1 . Working status and ethnicity have not been tabulated but one person in each group worked part time. All others (n = 22) were retired. All described their ethnicity as white (n = 24). Fourteen participants (58%) had a history of more than one fracture, with the proportions of fractures by spinal region as follows: lumbar 47%, lumbar and thoracic 18%, thoracic 35%. The history of OVFs ranged from 3 months to 8 years.
The gender distribution varied between groups, with all three men randomly allocated to the control group. The control group scored slightly lower on most outcomes, suggesting slightly lower disease severity.
Owing to small group differences at baseline, analysis was conducted on change scores (week 4 values minus baseline values). Table 2 demonstrates fairly consistent improvements in both groups. The mean difference favours taping in most outcomes, the only exception being the QUALEFFO-41 general health perception subscale. Generally, point estimates for standardized effect sizes were small to medium. The largest effect sizes were for pain and physical function outcomes. As expected in such a small study, group differences and effect sizes were associated with relatively large confidence intervals, all of which crossed zero. Table 3 illustrates the health resource use reported over the previous 4 weeks at baseline, giving insight into "usual care". Healthcare consultations were most frequent for physiotherapists (approaching an average of one consultation per person). Two-thirds of patients used medications prescribed for their OVF, with an average of two prescriptions for those who used them. Although not reported separately, there were no obvious differences at baseline between groups in potential confounders related to healthcare consultations or medication. Healthcare resource data were successfully collected at week 4 but are not presented owing to a lack of obvious trends. 
| Resource use

| Adverse events
Three participants (23%) allocated to taping reported a mild skin reaction and were advised to discontinue using it. All events were reported to the study sponsor. No other adverse events were reported. In all cases, the skin reaction settled within a few days without further medical intervention. All three participants completed follow-up and were retained as part of an intent-to-treat analysis.
| Use and acceptability of the taping device
On average, participants used 17 of the 28 devices supplied. The median reported duration of use was 21-24 days, for a median of 16-18 hours per day. Nine out of 13 (69%) wore the device in bed at night, although 4/9 (44%) reported it as "uncomfortable" when they did so. Nine out of 13 (69%) required assistance to put on the device.
Of those who required help, 5/9 then reported that it was "easy" to apply, but 2/9 still reported it as "difficult" and 2/9 as "neither easy nor difficult". Of those who did not require help to apply the device, 1/4 found it "easy", 1/4 found it "neither easy nor difficult" and 2/4
found it "difficult". Specific difficulties reported included removing the device from the packaging, parts of the device sticking together, and having to twist to view the application in a mirror.
| Acceptability of the outcome measures
All participants (n = 24) rated the acceptability of study questionnaires at a median of 2 ("acceptable").
| Sample size calculation
A minimum clinically relevant difference is not available for the QUALEFFO-41. A prospective sample size calculation for a definitive RCT was therefore made using the VAS pain on movement, as this was considered to be more functionally relevant than pain at rest. Dworkin et al. (2008) The largest standardized effect size was for the physical function subscale of the QUALEFFO-41 scale (Cohen's d = 0.77), followed by the total QUALEFFO-41 score (0.67). The potential effects therefore extend across pain, function and QoL. However, caution is warranted owing to the large confidence intervals around these estimates, and these preliminary findings need to be replicated in a definitive RCT.
A relatively large proportion of participants (23%) developed a mild skin reaction when using taping. Smith and Zirwas (2015) reported that, although 0.347% of patients reported an allergy to medical tape, the true value was estimated to be much lower, at 0.033%. Non-allergic tape reactions are therefore likely to be much more common than allergic ones. Non-allergic reactions may be caused by skin inflammation due to factors such as previous skin damage, skin softening, physical distortion, hair removal, tape preventing the removal of skin irritants, and repeated removal of the uppermost layer of skin (Smith & Zirwas, 2015) . The high prevalence of such reactions in the present investigation may relate to the older population investigated, whose skin might be expected to be more fragile. Other the devices is that they can be self-applied, it was clear that the majority of participants (69%) required assistance. Of the four participants who self-applied the devices, only one reported that this was "easy".
Such knowledge is important to inform patient information. Greig et al. (2008) 
| Strengths and limitations
The present investigation was a feasibility study, so definitive statements related to effectiveness cannot be made. Randomization was not stratified by gender, and all men were allocated by chance to the control group. Future research should address this, and also the lack of diversity of the sample with regard to ethnicity. There are no accepted cut-off scores for severity for the QUALEFFO questionnaire.
However, it should be noted that participants in the present investigation generally had higher QUALEFFO scores than previously reported cohorts,. For example, the sample included in the initial validation of the QUALEFFO questionnaire (Lips et al., 1999) had a mean total QUALEFFO score of 35.3. Participants in the present sample were also older than those reported by Lips et al. (1999) , who had a mean age of 66.3 years. Again, future work should aim to recruit a representative sample in relation to condition severity and age.
The study outcome measures were largely acceptable. Information on recruitment rates and estimates of variability have been obtained and have informed a sample size calculation for a definitive trial. The study also demonstrated the feasibility of collecting health resource use data to inform a future economic evaluation. A major limitation was the very brief follow-up (4 weeks), and a future trial should evaluate the longer-term effects of the device. Similarly, researcher blinding should also be addressed.
| CONCLUSION
The postural taping device has demonstrated the potential to improve pain, function and QoL, which is notable for such a simple device. The study procedures were largely acceptable to participants. A more extensive pilot RCT, with a longer follow-up, is recommended prior to a definitive trial.
